Ascletis Pharma Inc.

HKSE 1672.HK

Ascletis Pharma Inc. Total Non-Current Liabilities for the year ending December 31, 2023: USD 1.16 M

Ascletis Pharma Inc. Total Non-Current Liabilities is USD 1.16 M for the year ending December 31, 2023, a -10.42% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.

Ascletis Pharma Inc. Total Non-Current Liabilities for the year ending December 31, 2022 was USD 1.30 M, a -16.74% change year over year.
Ascletis Pharma Inc. Total Non-Current Liabilities for the year ending December 31, 2021 was USD 1.56 M, a -12.56% change year over year.
Ascletis Pharma Inc. Total Non-Current Liabilities for the year ending December 31, 2020 was USD 1.78 M, a -14.39% change year over year.
Ascletis Pharma Inc. Total Non-Current Liabilities for the year ending December 31, 2019 was USD 2.08 M, a 111.29% change year over year.

Key data

Date	Total Non-Current Liabilities	Shareholders' Equity	Other Liabilities	Total Liabilities

HKSE: 1672.HK

Ascletis Pharma Inc.

CEO	Dr. Jinzi Jason Wu Ph.D.
IPO Date	Aug. 1, 2018
Location	China
Headquarters	Building D
Employees	219
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Vaccines

Description

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. The company offers Ritonavir oral tablet, a pharmacokinetic booster of various oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug Paxlovid; ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating chronic hepatitis B (CHB) and human immunodeficiency virus functional cure; ASC42 for chronic hepatitis B functional cure; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC, ASC44F FDC, and ASC45F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma, drug resistant breast cancer, and KRAS mutant non-small cell lung cancer; ASC61 and ASC63 for advanced solid tumors; ASC60 to treat solid tumors; and ASC40 for the treatment of acne, Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the People's Republic of China.

Key trends

Past 5 years